We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




German Partners to Develop Biomarker Platform for Targeted Cellular Therapies

By LabMedica International staff writers
Posted on 05 Mar 2012
Two German biotech companies are cooperating in a personalized medicine project to develop a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.

The partnership will exploit the complimentary assets of apceth GmbH & Co. More...
KG (Munich, Germany), and Indivumed GmbH, (Hamburg, Germany). apceth is known for its development and clinical application of pioneering stem cell and gene therapies, particularly for the treatment of malignant diseases. Indivumed maintains a comprehensive tumor database and high-quality biobank for the development of new cancer diagnostics and therapies, and provides state-of-the-art services for biomarker discovery based on viable primary human biospecimens.

The goal of the new project is to predict the response to targeted cellular/ gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s innovative cell and cell-based gene therapeutics.

The partners have indicated that the combination of apceth’s therapeutic approach and Indivumed’s biomarker platform has the potential to drive future cancer therapeutics and pharmaceutical innovation, thereby making the promises for personalized medicine a reality.

Related Links:
apceth GmbH & Co. KG
Indivumed GmbH




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.